Dermira, Inc. (NASDAQ:DERM) Files An 8-K Other Events
Item8.01
| Other Events. |
On May10, 2017, Dermira, Inc. (Dermira)
issued a press release announcing the pricing of its offering of
$250,000,000 aggregate principal amount of 3.00% Convertible
Senior Notes due 2022 (the Notes) to
qualified institutional buyers to Rule 144A under the Securities
Act of 1933, as amended. Dermira also granted the initial
purchasers of the Notes a 30-day over-allotment option to
purchase up to an additional $37,500,000 aggregate principal
amount of Notes. A copy of the press release announcing the
pricing of the Convertible Senior Notes is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit Number |
Description |
|
| 99.1 |
Press release dated May10, 2017 announcing the pricing of the Notes. |
About Dermira, Inc. (NASDAQ:DERM)
Dermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne. Dermira, Inc. (NASDAQ:DERM) Recent Trading Information
Dermira, Inc. (NASDAQ:DERM) closed its last trading session down -4.89 at 27.27 with 4,894,975 shares trading hands.